Mast cells may be cultured from human peripheral blood in the presence of recombinant human stem cell factor (rhSCF). The characteristics of the cells in peripheral blood that give rise t o mast cells are unknown. Because mast cell precursors in human marrow are CD34+, human peripheral blood mononuclear cells from patients with mastocytosis and normal controls were sorted on the basis of CD34 expression and the positive and negative cell populations were cultured in rhSCF, recombinant human interleukin-3 (rhlL-31, or both for 6 weeks. Cell cultures were examined every 2 weeks for total and mast cell number and cell differential using Wright Giemsa and acid toluidine blue stains and antibodies to mast cell tryptase and chymase, cell-associated histamine, and expression of CD34, c-&it, Fc,RI, and Fc,.RII using flow cytometric analysis. The ultrastructural anatomy of mast cells was examined by electron microscopy. Peripheral blood CD34+ cells cultured in rhSCF with or without rhlL-3 gave rise t o cell cultures consisting of greater than 80% mast cells by 6 weeks. CD34+ cells cultured in rhlL-3 alone did not give rise t o mast cells, whereas rhlL-3 plus rhSCF increased the final mast cell number eightfold when compared with cells cultured in rhSCF alone. Mast cells increased concomitantly M AST CELLS ORIGINATE from pluripotential hematopoietic cells within the marrow',2 and reach their mature phenotype within t i s s~e s .~ It is believed that the mast cell progenitors arising within bone marrow (BM) reach peripheral tissues after distribution via the peripheral circulation. Indeed, mast cells cannot be identified in peripheral blood (PB) under normal conditions: and a murine mononuclear cell population separated by density gradients and giving rise to mast cells has been de~cribed.~ The concept is further supported by the demonstration that human PB mononuclear cells (PBMC) cultured in conditioned medium derived from human placenta, supernatants from a human lymphocyte leukemic cell line, and phytohemagglutininstimulated normal human peripheral blood lymphocytes give rise to histamine-containing colonies resembling mast cells/ basophik6 More recently, it has been shown that human cord blood and blood from adult donors cultured in the presence of c-kif ligand (stem cell factor [SCF]) give rise to human mast cells defined by traditional criteria.'.*
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In an attempt to identify the mast cell progenitor within human PB, we hypothesized that, as is true for human marrow, this cell would be CD34+, and might or might not express Fc,RI.
As will be shown, a CD34' Fc," cell population within PB does give rise to mast cells when cultured in SCF. Interleukin-3 (IL-3) enhances this SCFdependent mast cell proliferation. The CD34-population does not give rise to mast cells. The kinetics of the appearance of mast cells; their morphologic features; expression of c-kif, Fc,RI, and Fc,RII, and cell-associated histamine are also examined. The number of mast cells arising from CD34+ cell populations obtained from normal subjects and patients with indolent or aggressive mastocytosis9 is compared.
MATERIALS AND METHODS
Cell separation. PB was obtained from 8 patients with indolent systemic mastocytosis, 2 patients with aggressive mastocytosis, and with a decrease in large undifferentiated mononuclear cells. CD34-cells did not give rise t o mast cells. Histamine content per cell at 6 weeks was approximately 5 pg. Electron microscopy of 4-week cultures showed immature mast cells containing predominantly tryptase-positive granules that were either homogeneous or contained lattice structures, partial scroll patterns, or central dense cores and mixtures of vesicles, fine granular material, and particles. The CD34' population at day 0 expressed Kit (66%) and Fc,RII (95%). but not Fc,RI, by fluorescence-activated cell sorter analysis. At 6 weeks, CD34+-derived mast cells exhibited Fc,RI in addition t o Kit and FcJtII, and were negative for CD34 antigen. Patients with mastocytosis showed a higher number of mast cells per CD34+ cell cultured compared with normal controls. Thus, the mast cell precursor in human peripheral blood is CD34+/FceRl-and gives rise t o mast cells in the presence of rhSCF with or without rhlL-3, and the number of mast cells arising per CD34+ cell in culture is greater when the CD34+ cells are obtained from patients with mastocytosis compared with normal subjects. This is a US government work. There are no restrictions on its use.
3 normal controls according to an Institutional Review Board approved protocol and after obtaining informed consent. BM was similarly obtained from 3 patients with indolent systemic mastocytosis after obtaining informed consent. PBMC and BM-derived mononuclear cells (BMMC) were obtained using Ficoll Hypaque (density, 1.077 to 1.080 g/mL; Organon Teknika CO, Durham, NC). CD34+ cells were separated from PBMC and BMMC by an avidin column using a Ceprate LC CD34 kit (CellPro, Inc, Bothell, WA), as described."," Briefly, PBMC or BMMC were centrifuged at 8OOg for 10 minutes and resuspended in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) twice at a density of 1 X 10' cellslml. PBMC or BMMC were then incubated at room temperature for 25 minutes in the presence of mouse antihuman CD34 IgM monoclonal antibody (CD34 MoAb, 40 pg/mL). Cells were washed twice, resuspended to 100 x lo6 cellslmL in PBS with 1% BSA, and incubated at room temperature for an additional 25 minutes in the presence of biotinylated rat antimouse IgM (0.5 pgl mL). Cells were next washed once, resuspended in PBS containing 5% BSA, and placed over an avidin column. The column was washed with 6 mL PBS to collect the CD34-cell population, after which the column was agitated to release the CD34+ cell population. The purity of the sorted CD34' cell population was examined by flow cytometry using mouse anti-HPCA-2 MoAb (directed against a different CD34 epitope than the primary antibody used for the cell separation; IgG, ; Becton Dickinson, San Jose, CA), and ranged from 75% to 95%. Cell viability as assessed by trypan blue dye exclusion was greater than 95%.
Cell culfure. PBMC-and BMMC-derived CD34' and CD34-cell populations (2 X IO5 cells/mL) were cultured in the presence of recombinant human (rh) IL-3 (30 U/mL; Genzyme CO, Boston, MA) and rhSCF (100 ng/mL; Genzyme) alone or in combination in RPM1 1640 medium containing 4 mmol/L L-glutamine, 1 mmollL sodium pyruvate, 100 U/mL penicillin, 100 g/mL streptomycin, 0. I mmol/L nonessential amino acids (Bio-fluids, Inc. Rockville, MD), 5 X IO-' molL 2-mercaptoethanol (Sigma, St Louis, MO), and 10% autologous serum. The use of human serum was based on initial experiments in our laboratory, which showed that PBMC cultured in human serum gave rise to more mast cells than when PBMC were cultured in the presence of either bovine or fetal calf serum. Cells were cultured in 24-well plates for up to 6 weeks at 37°C in a 5% CO2 humidified atmosphere. Cells were fed twice weekly by removing one-half of the culture media and replacing it with freshly prepared media together with the appropriate growth factors. Cell number was enumerated every 2 weeks using either a hemocytometer or an automated cell counter (Coulter Electronics Inc. Hialeah, FL).
Histochemical stains. At 2-week intervals, aliquots of cultured cells were spun onto glass slides in a cytocentrifuge (Shandon Southern Instruments Inc, Sewickley, PA), allowed to air dry, and stained with Wright-Giemsa using an Ames Hematek automated slide stainer (Miles Laboratories Inc. Elkhart, IN). Acid toluidine blue (pH 1 .0), which stains all mast cells, was performed on slides fixed in Mota's lead acetate.'' Slides were examined at high magnification ( X 1,250) under oil.
Immunohistochemistr~. Cytocentrifuge preparations were subjected to immunohistochemical labeling for tryptase and chymase to determine the presence and phenotype of mast cells.'?.14 In brief, after Carnoy's fixation, inhibition of endogenous peroxidase, and incubation with murine nonimmune serum, slides were incubated for 1 hour at room temp with a mixture of alkaline phosphataseconjugated murine antitryptase MoAb ((33-AP; 6 pg/mL; Chemicon, Temecula, CA) and biotinylated murine antichymase MoAb (B7-B; 4 pg/mL; Chemicon). Tryptase-positive cells were stained blue by the addition of fast blue RR and naphthol AS-MX phosphate. Slides were then washed and chymase-positive cells were visualized in brown using indirect immunoperoxidase staining." Percentages of total cells comprising mast cells were determined under phase contrast microscopy to identify unstained cells on the slides.
Electron microscopy. CD34' 4-week cultures were prepared for chymase and tryptase labeling and electron microscopy as described.' Briefly, cell suspensions were fixed in a mixture of 2% paraformaldehyde and 1 .S% glutaraldehyde in 0.1 molL sodium cacodylate buffer, pH 7.3, for 3 hours at room temperature. After washing with cacodylate buffer, the cells were suspended in warm 2% agarose and centrifuged. Cell pellets were postfixed for 1 hour at room temperature in cacodylate-buffered 1% Os04, dehydrated in a graded ethanol series, and embedded in Embed 812/Araldite 502. Thin sections were cut and mounted on uncoated nickle grids. For immunolabeling, sections on grids were placed on a 0.56 mol/ L (saturated) aqueous solution of sodium metaperiodate for 70 minutes at room temp, washed with water followed by PBS, and incubated with goat IgG (0.5 mg/mL) for 1 hour at room temperature. Grids were incubated overnight at 4°C with either murine antitryptase MoAb ( Histcmine assczys. To determine cell-associated histamine, aliquots of cells were washed, resuspended in PBS at a concentration of 5 X 10' cells/mL, and placed in a water bath at 100°C for 10 minutes.'' Samples were then analyzed for histamine content using an immunoassay that uses MoAbs raised against acylated histamine" (Amac Inc, Westbrook, ME). Flow cyrornetric analysis. Cell surface marker expression was assessed by flow cytometry. At designated times, cells were washed twice by centrifugation at 800g for 10 minutes and resuspended in Hanks' Balanced Salt Solution (HBSS) without calcium, magnesium, or phenol red, containing 0.2% BSA at a concentration of IO' cellslml. Analyses were then made by direct immunofluorescence for Kit expression using a phycoerythrin (PE)-conjugated mouse MoAb directed against Kit (IgM; Amac), for CD34 expression using fluorescent isothiocyanate (F1TC)-conjugated mouse antiLCD34 (HPCA-2; Becton Dickinson), and for Fc,RI using FITC-conjugated human IgE as describedIx; and by indirect immunofluorescence for Fc,RII using biotin-conjugated 2.4G2 MoAb and streptavidin PE. Nonspecific fluorescence was assessed by substituting isotype specific antibody for the MoAb in the case of Kit, CD34, and Fc,RII, and by preincubating an aliquot of the cells with 100 pg/mL of purified monoclonal IgE before adding the FITC-conjugated IgE in the case of Fc,RI. Flow cytometric analysis was performed on an Epics 753 (Coulter Electronics) with an Argon laser (Coherent Inc. Palo Alto, CA) tuned to 488 nm, wavelength 300 mW. Multiparameter data acquisition and display system software (Coulter Electronics) and a four-decade logarithmic amplifier were used for statistical analysis and the data displays.
RESULTS
Kinetics cf the appearance of mast cells from PBMCderived CD34' cells. We have previously shown that human mast cells originate from CD34' cells within the BM.' Because mast cell precursors appear to be present in PB? we hypothesized that mast cell progenitors in blood were also CD34'. PBMC were sorted on the basis of CD34 expression, and the positive and negative populations were cultured in the presence of either rhIL-3, rhSCF, or both. Approximately 5 X lo5 CD34' cells were isolated per IO' total PB nucleated cells. When CD34' were cultured in the presence of rhIL-3 alone, total cell number decreased over time, and no mast cells could be identified (Fig IA) . Cells cultured in the presence of rhSCF or rhSCF and rhIL-3 increased in average total cell number from 1 X IO4 cells on day 0 to 1.1 X IO' and 8.4 X IO4 cells at 6 weeks, respectively (Fig 1B and C) . Mast cell number in these cultures similarly increased from 0 on day 0 to an average of 0.8 X lo4 and 8 X 10' at 6 weeks, respectively. Thus, approximately 1 mast cell was obtained per CD34' cell cultured in rhSCF alone, and 8 mast cells were obtained per CD34' cell cultured in rhSCF plus rhIL-3. CD34-cells decreased in number under all conditions and did not give rise to mast cells (Fig lA, B, and C) . Unsorted PBMC cultured in rhSCF with or without rhIL-3 gave rise to similar numbers of mast cells from a starting population of IO9 nucleated cells (data not shown). These experiments show that mast cell progenitors in the peripheral circulation are CD34+, and that there are no CD34-mononuclear cells in the peripheral circulation that can give rise to mast cells. SCF is thus both necessary and sufficient for the growth of mast cells from human PB, although IL-3 enhances SCF-dependent mast cell growth. We have observed similar responses to SCF and IL-3 using murine PBMC-derived mast cells." To further explore the fate of CD34+ cells cultured in the presence of rhSCF or rhSCF and rIL-3 (Fig 1B and C) , we next examined the type of cells observed in these cultures. At day 0, cultures were composed of 93% large mononuclear cells, 6% myelocytic cells, and 1% monocytes (Fig 2A and  B) . No metachromatic cells, as assessed by acid toluidine staining, were noted. With time, the percentage of large mononuclear cells decreased, concomitant with an increase in the percentage of metachromatic cells. The percentage of monocytes under both conditions increased slightly at 4 weeks to an average of 6% of total cells in culture, whereas the number of myelocytes decreased. By 6 weeks, more than 80% of cells cultured in rhSCF alone were metachromatic, whereas more than 90% of cells cultured in rhSCF and rhIL-3 exhibited metachromatic staining. In data not shown, by 8 weeks virtually all cells were metachromatic under both conditions. Similarly, at 2 weeks, about 50% of metachromatic cells exhibited morphologic characteristics of basophils, whereas at 4 weeks 85% were recognized as mast cells. Cell counts by 6 weeks were confirmed by immunohistochemistry for tryptase (see below).
Characterization of cultured cells. By 6 weeks, PBMCderived CD34' cells, as shown under phase microscopy in Fig 3A, primarily consisted of mast cells as determined by acid toluidine blue staining (Fig 3B) . Cells were also examined for the expression of mast cell tryptase and were uniformly positive for this enzyme found in both mucosal and connective tissue type mast cells (Fig 3C) . Occasional cells were lightly positive for chymase (data not shown), an enzyme associated with connective tissue mast cells. Cultures were also examined by electron microscopy at 4 weeks, when the majority of cells in culture were identified by light microscopy as mast cells. As can be seen in Fig 4, ultrastructural examination of PBMC-derived CD34' cells showed immature mast cells (Fig 4A) . These cells exhibited a wide variety of characteristic features of human mast cells cultured from other tissues.2" These characteristics included mature granules with homogeneous dense material (Fig 4B) , granules containing characteristic lattice or crystalline arrays (Fig 4C) , and granules with partial or nondiscrete scroll patterns (Fig 4D) . Immature granules contained central dense cores and mixtures of vesicles, fine granular material and particles (Fig 4E) . Immunogold labeling for tryptase was positive in all granule types (Fig 4A through D) . A minority of granules were also faintly positive for chymase (data not shown). The cell nuclei were large and often lobulated. The surface showed numerous short narrow cytoplasmic extensions. Cytoplasmic organelles included clusters of lipid bodies, mitochondria, golgi, and free ribosomes, all consistent with immature mast cells.
To further characterize the cells developing in the presence of rhSCF and rhIL-3 in culture, we next examined cell associated histamine. As can be seen in Fig 5, histamine content per cell increased from an average of 0.01 t 0.01 pg/cell at week 1 to an average of 5.00 2 0.45 pg/cell at 4 weeks, after which the histamine per cell did not significantly change. This histamine content per cell at 6 weeks is similar to the amount of histamine reported to be present in human lung-derived mast cells.*'
Surface marker expression of PBMC-derived CD34' cells. Murine studies on the differentiation of mast cells have suggested that mast cell progenitors express Fc,RI and Fc,RII.'* Thus, we examined the CD34' cell population initially and after 6 weeks in culture for the expression of these cell surface molecules as well as for Kit and CD34. At day 0, the majority of cells expressed CD34 (85%), Kit (50%), and Fc,RII (85%). but no Fc,RI (Fig 6A through D) . CD34' cells incubated with human IgEpP followed by incubation with goat antihuman IgE 10 nm gold did not show surfaceassociated human IgE, consistent with the absence of significant numbers of Fc,RI (data not shown). Within the CD34' cells, 65% were Kit' and 95% were Fc,RII+. At 6 weeks, cells now expressed Fc,RI, Fc,RII, and Kit, but no CD34 (Fig 6E through H) . CD34 expression was found to be lost within 3 days in culture and before Fc,RI could be detected (data not shown). Thus, circulating CD34' mast cell progenitors do not express significant membrane-associated Fc,RI.
Kinetics of the appearance of mast cells from BMMCderived CD34' cells. We have previously shown that mast cells arise from CD34' cells harvested and sorted from the BM by immunomagnetic beads.' To compare the kinetics of the appearance of mast cells from BMMC-derived CD34' cells and from PBMC-derived CD34' cells, we next examined the kinetics of appearance of mast cells from BMMCderived CD34' cells in the presence of rhSCF and rhIL-3. The number of CD34' cells generated from BMMC was on the average approximately 13 times higher than from PBMC (6.8% compared with OS%, respectively). As can be seen in Fig 7, only CD34' cell gave rise to mast cells. The temporary peak of total cell number at the second week suggests that BMMC-derived CD34' cells may initially proliferate and give rise to more committed progenitor cells of lineages other than the mast cell lineage, but that eventually only the mast cell progenitors survive under the conditions chosen. Differential counts at the second week showed that 95% of cells were large mononuclear cells (data not shown). At 6 weeks, the average total cell number and mast cell number were similar to the number of cells that were cultured from PBMC-derived CD34' cells. Fig 8 and compared with the appearance of mast cells from CD34' cells obtained from 3 normal subjects and 2 patients with aggressive mastocytosis. As can be seen in Fig  X, the number of mast cells observed at 4 weeks was similar when the CD34' cells were obtained from patients with indolent systemic mastocytosis or normal subjects, although by 6 weeks an approximate twofold increase in mast cells was seen in cultures from indolent systemic mastocytosis patients compared with cultures obtained from normal subjects. In contrast, when CD34' cells were obtained from patients with aggressive mastocytosis, both total cell number and mast cell number was increased at 2, 4, and 6 weeks when compared with data obtained from patients with indolent systemic mastocytosis and from normal subjects. The basis for the disparity in the growth curves is under exploration. Preliminary experiments suggest that these results are not influenced by serum of specific donors. In one instance, CD34' cells from a normal subject exhibited identical growth pattern characteristics when grown in autologous normal serum or heterologous serum from a patient with aggressive mastocytosis. In a second experiment, CD34' cells from a patient with aggressive mastocytosis were cultured for 3 weeks in autologous serum, rhTL-3, and rhSCF. The cells were then divided, with half of the cells cultured in autologous serum, rhIL-3, and rhSCF, and the second half cultured in heterologous normal human serum, rhIL-3, and rhSCF. After 3 weeks, the total mast cell number was similar in both cultures.
DISCUSSION
The data presented here clearly show that the mast cell precursor in human PB is CD34' (Fig 1) . These circulating CD34' cells morphologically resemble large mononuclear cells and contain no granules (Fig 2) . able high-affinity receptor for IgE by fluorescence-activated cell sorter analysis, but have receptors, as expected, for SCF (Fig 6) . They also express Fc,RII. These mast cell progenitors in culture become CD34-within 3 days. By 6 weeks, the cells that have developed in culture are largely mast cells and are Fc,RI+/Kit+. As cultured cells developed granules, they also can be shown to accumulate histamine (Fig S ) .
The CD34+ cells by 6 weeks in culture consisted of greater than 80% mast cells. These mast cells were toluidine blue+, expressed Fc,RI, contained histamine, and stained with antibody to mast cell tryptase (Fig 3) . Less than 3% of cultured mast cells at 6 weeks stained with antibody to chymase. Tryptase+/chymase-mast cells are generally considered to be of the mucosal phenotype, and it may be that additional cytokines are required for the expression of chymase, which is a marker of the connective tissue mast cell phenotype. Modulation of the mast cell granule phenotype has been described for murine mast cells. ' The ultrastructural anatomy of mast cells has been described for mast cells from human tissues, and mast cells either arising from cord blood or fetal liver.'*14 However, in previous reports in which mast cells were grown from adult human blood, no ultrastructure was reported.' For this reason, we performed a detailed analysis using electron microscopy of mast cells arising in our cultures. Ultrastructural granule patterns in mast cells cultured from adult blood in this report were similar to those reported for mast cells from cord blood or fetal liver:' 4 in that they variably contained granules with homogeneously dense contents, vesicles, nondiscrete scrolls, and particles. However, mast cells from adult blood differed in that granules containing lattice or crystalline arrays could also be identified (Fig 4C) . The crystalcontaining granules are usually considered to be characteristic for connective tissue type mast cells, but have been seen when immature human cord blood-derived mast cells were cocultured with 3T3 fibroblasts." rhSCF is required for the development of mast cells from the CD34' cell population in marrow and blood. This is not surprising, because it has been reported that mast cells can be cultured from human cord blood, adult PB, and fetal liver cells in rhSCF However, it was unexpected that rhIL-3 would increase mast cell yield eightfold. The use of rhIL-3 and human sera (in place of fetal calf serum) in the presence of rhSCF, as first reported here, provides for a culture system that reproducibly gives rise to substantial numbers of human mast cells.
As shown in Figs 2 and 7, CD34+ cells from human PB or BM cultured in rhSCF with or without rhIL-3 give rise to a cell population dominated by mast cells at 6 weeks. Both rhIL-3 and rhSCF are growth factors that effect multiple hematopoietic cells early in differentiation. However, in the case of hematopoietically derived cells such as neutrophils or eosinophils, receptors for SCF appear to be downregulated in number and terminal differentiation requires specific growth factors such as granulocyte colony-stimulating factor or IL-S. In contrast, mast cells continue to express c-kit (Fig  6) , and thus continue to develop in these cultures to the point at which by 6 weeks few if any other cell types can be identified. For personal use only. on October 26, 2017. by guest www.bloodjournal.org From An unexpected observation in this report was that CD34' cells from patients with aggressive mastocytosis yield increased mast cell numbers by 6 weeks when compared with CD34+ cells obtained from patients with indolent mastocytosis or normal subjects (Fig 8) . Preliminary experiments suggest that this is not caused by a serum factor as suggested by data that some forms of mastocytosis are associated with increased amounts of immunoreactive SCF in the dermis,*' but rather by an inherent property of the CD34' cell population itself, perhaps reflecting a c-kit mutati0n.2~ What is intriguing about this observation is that it also parallels the in vivo data, which show that patients with aggressive mastocytosis more rapidly accumulate mast cells than those with indolent mastocytosis. The differences between mast cell numbers obtained from CD34' cell populations from patients with indolent mastocytosis is less remarkable when compared with normal subjects.
We have recently observed that mouse PBMC cultured in recombinant mouse (rm) SCF alone give rise to a virtually pure population of mast cells by 2 weeks, and mast cell number is enhanced by the addition of 1m1L-3.'~ Given the knowledge that human cells in culture characteristically grow more slowly that mouse cells in culture, the data obtained from the human studies reported here are virtually identical to similar studies in the mouse. This is the first demonstration then that mouse and human mast cell precursors in marrow (Fig 7) and PB (Fig 1) respond in a virtually identical fashion to mast cell growth factors given the improved culture conditions for mast cell cultures reported here. Compared with a previous study of PBMC cultured in rhSCF that by 35 days yielded a population of 0.2 to 7% mast cells,' we obtained a higher purity of mast cells and in greater number that we attribute to the use of autologous human serum. This appears to resolve the long-standing dispute as to apparent differences in mast cell growth characteristics between mice and humans, and supports again the use of mouse models to study the growth and differentiation of immunologic effector cells. Additionally, the improved culture conditions for human mast cells reported here should permit the wider study of human mast cell biology.
Hematopoietically derived cells, including neutrophils, eosinophils, basophils, and monocytes, circulate in mature form in blood. This study shows that mast cells clearly differ from this behavior. Not only do they not circulate in mature form, but they do not appear as sparsely granulated Fc,RI+ mast cell precursors, as has been suggested?' Rather, human mast cells in PB are derived from a CD34', Fc&-cell population. Not only is this true in normal subjects, but also for patients with mastocytosis, arguing against clonal expansion of differential mast cells in the etiology of this disease.
